67 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
Reviewers” means independent persons nominated by CRH or the Charity for the purpose of monitoring and reviewing work funded by the Charity … (or any successor body thereto) for the purpose of Clause 6.3 or 15.3.2; or
the Association of the British Pharmaceutical Industry (or any successor body
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
” means a preclinical toxicology study conducted for the purpose of assessing the potential hazards and risks of a pharmaceutical drug product … of ValenzaBio. ProBioGen shall not use such ValenzaBio Deliverables for any purpose other than for the Services, and ProBioGen shall, except if permitted under
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
long as such control exists (and for this purpose, the term “control” means (a) the power to direct the management and policies of a Person (directly … for the purpose of obtaining, updating or maintaining any Regulatory Approval, in each case including any investigational medicinal product dossier solely
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, or product-specific foreground intellectual property, for the purpose of non-commercial, non-clinical scientific research.
The Company is obligated
8-K
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
licensed product, or product-specific foreground intellectual property, for the purpose of non-commercial, non-clinical scientific research.
Tenet
8-K
EX-99.4
dtcbr3 lkegs5g
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.6
mjym3s 5bmt685xip
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.2
y9a a569o
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-10.1
mw75w3b0z ip7
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
sl7p ku2w2yp
4 Jun 24
Proxy related to merger
8:00am
PREM14A
l0xkq9fjwsmji8
17 May 24
Preliminary proxy related to merger
4:36pm
PREM14A
zqxj6 siqo92o8
17 May 24
Preliminary proxy related to merger
4:36pm
10-K/A
pcqdwd kr3gc6
29 Apr 24
Annual report (amended)
4:02pm
DEFA14A
tdmts8so
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
8rsl bqb4
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-2.1
wmvml6
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
kny 6pl7j
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.1
6m6siv9uwp
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am